mRNA—From COVID-19 Treatment to Cancer Immunotherapy

Abstract

This review provides an overview covering mRNA from its use in the COVID-19 pandemic to cancer immunotherapy, starting from the selection of appropriate antigens, tumor-associated and tumor-specific antigens, neoantigens, the basics of optimizing the mRNA molecule in terms of stability, efficacy, and tolerability, choosing the best formulation and the optimal route of administration, to summarizing current clinical trials of mRNA vaccines in tumor therapy.

Keywords

• mRNA
• COVID-19
• cancer vaccine
• tumor antigens
• neoantigens
• immunotherapy